GlassScriptPhysician profile
Robert F Lindgren
NPI 1033299375
$1,434.97
in general payments reported to CMS, 2019-2025
22 companies · $61.12 in 2025
The $61.12 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $209 · 2021: $297 · 2022: $304 · 2023: $258 · 2024: $81.43 · 2025: $61.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.85 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $127.12 | 2022-2023 | Rexulti |
| Hologic Sales and Service, LLC | $121.34 | 2019-2023 | Acessa Provu System, Coolseal Generator |
| Novo Nordisk INC | $112.24 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Mylan Pharmaceuticals INC. | $87.61 | 2019-2022 | |
| Pfizer INC. | $83.73 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $71.36 | 2019-2021 | |
| Avion Pharmaceuticals | $63.09 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.98 | 2022 | |
| Evofem Biosciences, INC. | $53.12 | 2021 | |
| Astellas Pharma US INC | $51.86 | 2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $49.57 | 2022 | |
| Therapeuticsmd, INC. | $43.76 | 2019-2020 | |
| Organon LLC | $34.86 | 2021-2022 | |
| Coopersurgical, INC. | $30.10 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $26.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.88 | 2021 | |
| Glaxosmithkline, LLC. | $22.51 | 2023 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $22.11 | 2025 | Spravato |
| Agile Therapeutics, INC. | $19.74 | 2021 | |
| Ibsa Pharma INC. | $14.06 | 2022 | |
| Boston Scientific Corporation | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lindgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.